Neuroprotective effect of taurine against focal cerebral ischemia in rats possibly mediated by activation of both GABAA and glycine receptors
Introduction
Ischemic cerebral stroke is one of the leading causes of human death and disability across the world. If patients are able to survive the acute phase of cerebral infarction, they may encounter significant mental, physical, and economic stresses following neurological impairment. It is obvious that even a mild stroke could induce inevitable adverse consequences on each individual, their family and society due to the different extent of impairment of their daily life ability and vocational capacity. Up to now, treatment of ischemic cerebral stroke remains unsatisfactory (Cheng et al., 2004). In contrast to thrombolytics, neuroprotective agents, which have been proved promising in animal stroke experiments, have provided disappointing results in all clinical human trials (Jonas et al., 2001, Gladstone et al., 2002, Curry, 2003, Cheng et al., 2004). In fact, those neuroprotective agents in clinical trials of stroke intervention failed to produce beneficial results because their actions were too weak, or their application was too late as predicted from the animal models, i.e., “too little and too late” as pointed out by Jonas et al. (2001). However, the recent success of a trial of “FAST-MAG” therapy (Saver et al., 2004) fueled our interests in developing new neuroprotective therapies for cerebral stroke management.
Taurine, a β-amino acid, presents in high concentrations in the mammalian central nervous system (CNS) (Huxtable, 1989). It is believed to be involved in osmoregulation and cell volume adjustments (Huxtable, 1992, Hussy et al., 1997). Growing evidences suggest that taurine may function as a potent candidate of inhibitory neurotransmitter or modulator to regulate neuronal activity in many cerebral areas (Haas and Hosli, 1973, Huxtable, 1989, Hussy et al., 1997, Jiang et al., 2004). As an inhibitory amino acid in the CNS, taurine could activate glycine receptors (GlyRs) or γ-aminobutyric acid receptors (GABAR), showing the characteristics of a partial or full agonist of strychnine-sensitive GlyR and/or GABAAR (Haas and Hosli, 1973, Horikoshi et al., 1988, Hussy et al., 1997, Mori et al., 2002, Jiang et al., 2004). In adult individuals, activation of these two receptors will induce an inward Cl− movement and neuronal hyperpolarization, thus reducing neuronal excitability. Such activation can be used to antagonize cytotoxic effect of glutamate by counteracting neuronal depolarization and subsequent cascade of biochemical events that result in cell death during cerebral stroke (Green et al., 2000, Schwartz-Bloom and Sah, 2001).
Although controversy remains (Vaishnav and Lutsep, 2002, Lazar et al., 2003), several agents that could potentiate GABAergic synaptic neurotransmission have shown neuroprotective efficacy in acute cerebral ischemia (Green, 1998, Aerden et al., 2004). Moreover, in the recent two decades, taurine was proved protective on neurons which were exposed to many cell-damaging conditions (Kearns and Dawson, 2000, O'Byrne and Tipton, 2000, Saransaari and Oja, 2000, Louzada et al., 2004), including oxidants (such as hypochlorous acid and 1-methyl-4-phenylpyridinium), excitatory amino acids, hypoxia, and ischemic insults.
Whether the neuroprotective effect of taurine is mediated through GABAR or GlyR remains uncertain. Studies reported so far, however, investigated mostly the prophylactic effects of taurine treatment on many cell-damaging conditions, little information is available concerning its possible therapeutic efficacy in acute cerebral stroke. Hence, in the present study, we compared the neuroprotective efficacy of taurine treatments before and after a temporary occlusion of the middle cerebral artery (MCA) in rats and observed the blunting effects of GABAR and GlyR antagonists.
Section snippets
Animals and MCAO surgery
Male Sprague–Dawley rats (250–280 g body wt) were offered by the Experimental Animal Center of Nantong University, Nantong, China. All procedures used in this study were in accordance with our institutional guidelines, which comply with international rules and policies. Rats were anesthetized using 2 ml enflurane in an ether jar, and maintained with 10% chloral hydrate (400 mg kg−1, i.p.). The MCA was occluded with a 4-0 silicone-coated nylon suture by surgical operation in terms of report by
Comparison of the effects of taurine pretreatment and post-treatment
Neurology deficit score was measured at 3 h and 26 h after MCAO, and was inhibited at both time points when taurine was used (Fig. 1A). Meanwhile, cerebral infarct volume was also reduced in both pre- and post-treatment groups (Fig. 1B and C). Taurine pre-treated before MCAO operation significantly decreased the neurology deficit score and infarct volume, and post-treatment of taurine displayed similar effects, with taurine pretreatment superior to post-treatment in both indices (P < 0.05). In a
Discussion
Using TTC staining and MRI in the present study, we proved that post-treatment of taurine after temporal MCAO could decrease cerebral damage volume, though this effect was not as strong as that of taurine pretreatment. Meanwhile, taurine post-treatment reduced neurology score and brain water content. It is suggested that post-treatment of taurine could exert a neuroprotective effect on the brain subjected to ischemia/reperfusion. Moreover, according to the observation of the dose-dependent
Acknowledgements
This study was supported by grants from the Administration of Science and Technology of Nantong (Project No. S30018), and the Administration of Education of Jiangsu (Project No. 2005-76), Jiangsu Province, China.
References (52)
- et al.
Diazepam reduces brain lesion size in a photothrombotic model of focal ischemia in rats
Neuroscience Letters
(2004) - et al.
Apoptotic signaling cascades
Progress in Neuro-Psychopharmacology & Biological Psychiatry
(2003) - et al.
Taurine transport at the blood–brain barrier: an in vivo brain perfusion study
Brain Research
(1995) - et al.
Neuroprotection for ischemic stroke: two decades of success and failure
NeuroRx
(2004) - et al.
Characterization of a sodium-dependent taurine transporter in rabbit choroid plexus
Biochimica et Biophysica Acta
(1994) - et al.
The macrosphere model: evaluation of a new stroke model for permanent middle cerebral artery occlusion in rats
Journal of Neuroscience Methods
(2003) - et al.
Cellular localization of tumor necrosis factor-α following focal cerebral ischemia in mice
Brain Research
(1998) Clomethiazole (Zendra) in acute ischemic stroke: basic pharmacology and biochemistry and clinical efficacy
Pharmacology and Therapeutics
(1998)- et al.
GABA potentiation: a logical pharmacological approach for the treatment of acute ischaemic stroke
Neuropharmacology
(2000) - et al.
The depression of brain stem neurones by taurine and its interaction with strychnine and bicuculline
Brain Research
(1973)
Taurine prevents ammonia-induced accumulation of cyclic GMP in rat striatum by interaction with GABAA and glycine receptors
Brain Research
Taurine and β-alanine act on both GABA and glycine receptors in Xenopus oocyte injected with mouse brain messenger RNA
Brain Research
Taurine in the central nervous system and the mammalian actions of taurine
Progress in Neurobiology
An optimized triphenyltetrazolium chloride method for identification of cerebral infarcts
Brain Research Protocols
Apoptosis and brain ischaemia
Progress in Neuro-Psychopharmacology & Biological Psychiatry
Taurine: new implications for an old amino acid
FEMS Microbiology Letters
Taurine improves the recovery of neuronal function following cerebral hypoxia: an in vitro study
Life Sciences
Na+- and Cl−-dependent transport of taurine at the blood–brain barrier
Biochemical Pharmacology
Tumor necrosis factor-α expression produces increased blood–brain barrier permeability following temporary focal cerebral ischemia in mice
Brain Research: Molecular Brain Research
Effects of taurine on acute ischemia reperfusional brain lesion in rats
Chinese Journal of Current Clinical Medicine
Time- and pressure-dependent changes in blood–brain barrier permeability after temporary middle cerebral artery occlusion in rats
Acta Neuropathology
Why have so many drugs with stellar results in laboratory stroke models failed in clinical trials? A theory based on allometric relationships
Annals of the New York Academy of Sciences
Hypotensive effect of taurine: possible involvement of the sympathetic nervous system and endogenous opiates
Journal of Clinical Investigation
Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions
Stroke
Programmed cell death in cerebral ischemia
Journal of Cerebral Blood Flow and Metabolism
Perfusion-weighted magnetic resonance imaging using a new gadolinium complex as contrast agent in a rat model of focal cerebral ischemia
Journal of Magnetic Resonance Imaging
Cited by (80)
Hippocampal region-specific endogenous neuroprotection as an approach in the search for new neuroprotective strategies in ischemic stroke. Fiction or fact?
2023, Neurochemistry InternationalCitation Excerpt :Ricci and colleagues also report a protective role where rat brain-cortical slices are subjected to oxygen and glucose deprivation, thanks to an impact in reducing cell-swelling (Ricci et al., 2009). Moreover, various studies have shown that exogenous taurine – which is able to cross the BBB (Salimaki et al., 2003; Tsuji and Tamai, 1996) – can improve neurological function significantly, reducing infarct volume after MCAO, regardless of the administration method (intraperitoneal or intravenous) and time (before or after ischemic injury), and also of dose size (across a 50–200 mg/kg range) (Sun et al., 2011, 2012; Sun and Xu, 2008; Wang et al., 2007a). The above studies observed that taurine's neuroprotective properties operate by inhibiting apoptosis, preserving mitochondrial function and blocking mitochondria-induced cell death, suppressing inflammation, and activating both GABA(A) and glycine receptors.
Mitochondria protecting amino acids: Application against a wide range of mitochondria-linked complications
2018, PharmaNutritionCitation Excerpt :Glycine and betaine, are repeatedly used as protective agents in different experimental models [39–42]. Glycine is also the subject of clinical trials for alleviating the adverse effects of serious complications such as stroke [43]. The impact of glycine and betaine in ameliorating oxidative stress and its deleterious consequences has been implicated as a significant mechanism for the cytoprotection provided by these chemicals [37,44–48].
Taurine alleviates malathion induced lipid peroxidation, oxidative stress, and proinflammatory cytokine gene expressions in rats
2017, Biomedicine and Pharmacotherapy